{
  "file": "THESE_CHENANI.pdf",
  "total_pages": 173,
  "pages_checked": 15,
  "pages_with_text": 15,
  "text_coverage_ratio": 1.0,
  "scanned_pdf": false,
  "abstract_fr": null,
  "abstract_en": null,
  "abstract_ar": null,
  "has_keywords_marker": true,
  "toc_items": [
    "INTRODUCTION ................................ ................................ .......... 1",
    "MALADES ET METHODE S................................ ....................... 3",
    "TABLEAUX RECAPITULATIFS ................................ ............... 30",
    "RESULTAS ................................ ................................ ..................... 34",
    "I-PRESENTATION CLINIQUE ................................ ................................ 35",
    "A-AGE ET SEXE ................................ ................................ ................ 35",
    "B-LE DELAI D’HOSPITALISATION ................................ ............... 35",
    "C-MODE DE REVELATION ................................ ............................. 35",
    "II-EXAMENS COMPLEMENTAIRE ................................ ....................... 36",
    "A-BIOLOGIE ................................ ................................ ...................... 36",
    "B-ENDOSCOPIE ................................ ................................ ................. 36",
    "C-RADIOLOGIE ................................ ................................ ................. 37",
    "1-Echographie ................................ ................................ ............ 37",
    "3-Opacifications barytées ................................ .......................... 38",
    "4-Angiographie digestive ................................ .......................... 38",
    "III-LOCALISATIONS ................................ ................................ ................ 39",
    "IV-BILAN D’EXTENSION ................................ ................................ ......... 39",
    "V-LE TRAITEMENT ................................ ................................ .................. 39",
    "A-TRAITEMENT CHIRURGICAL ................................ ................... 39",
    "B-TRAITEMENT MEDICAL ................................ ............................. 41",
    "VI-L’EXAMEN ANATOMOPATHOLOGIQUE ................................ ....41",
    "VII-EVOLUTION ................................ ................................ ........................ 41",
    "DISCUSSION ................................ ................................ ................. 42",
    "I-DEFINITION ................................ ................................ ............................. 43",
    "II-HISTORIQUE ................................ ................................ .......................... 43",
    "III-CONCEPT ACTUEL ................................ ................................ ............. 45",
    "IV-CLASSIFICATION ................................ ................................ ................ 46",
    "V-ETHIOPATHOGENIE ................................ ................................ ........... 49",
    "A-FREQUENCE ET INCIDENCE ................................ ..................... 50",
    "B-AGE ET SEXE ................................ ................................ ................ 51",
    "C-LOCALI SATIONS ................................ ................................ .......... 52",
    "D-CIRCONSTANCES DE DECOUVERTE ................................ ......53",
    "E-ASSOCIATION PATHOLOGIQUES ................................ ............. 54",
    "1-Triade de Carney ................................ ................................ ....51",
    "2-Maladie de Rechlinghausen ................................ ................... 55",
    "3-Formes familiales ................................ ................................ ...55",
    "VII-ETUDE PARACLINIQUE ................................ ................................ ..56",
    "A-BIOLOGIE ................................ ................................ ...................... 56",
    "B-ENDOSCOPIE ................................ ................................ ................. 56",
    "C-ECHOENDOSCOPIE ................................ ................................ ......57",
    "D-ECHOGRAPHIE ................................ ................................ ............. 61",
    "E-TOMODENSITOMETRIE ................................ .............................. 61",
    "F-IMAGERIE PAR RESONNANCE MAGNETIQUE ...................... 62",
    "G-ARTERIOGRAPHIE HYPERSELECTIVE ................................ ...63",
    "H-TOGD ................................ ................................ .............................. 63",
    "I-TRANSIT DU GRELE ................................ ................................ .....64",
    "J-L’OPACIFICATION COLIQUE ................................ ..................... 65",
    "K-LA TOMOGRAPHIE PAR EMISSION DE POSITION ............... 65",
    "CAPSULE ................................ ................................ ......................... 66",
    "M-PONCTION BIOPSIE A L’AIGUILLE FINE ............................... 66",
    "VIII -ETUDE ANATOMO -PATHOLOGIQUE ................................ ........ 67",
    "A-ASPECT MACROSCOPIQUE ................................ ....................... 67",
    "B-MICROSCOPIE OPTIQUE ................................ ............................ 68",
    "C-MICROSCOPIE ELECTRONIQUE ................................ ............... 71",
    "D-IMMUNOHISTOCHIMIE ................................ .............................. 71",
    "E-CYTOGENETIQUE ................................ ................................ ........ 76",
    "ANATOMAPATHOLIGIQUE ................................ .............................. 79",
    "X-PRONOSTIC ET FACTEURS PREDICTIFS DE MALIGNITE ......81",
    "A-INDEX MITOTIQUE ................................ ................................ ......82",
    "B-TAILLE DE LA TUMEUR ................................ ............................. 83",
    "C-ANTIGENE DE PROLIFERATION CELLULAIRE ..................... 86",
    "D-ATYPIES CYTO -NUCLEAIRES ................................ ................... 87",
    "E-AUTRES FACTEURS PRONOSTIQUES ................................ ......87",
    "XI-TRAITEMENT DES TUMEURS STROMALES DIGESTIVES .....88",
    "A-MOYENS THERAPEUTIQUES ................................ .................... 88",
    "1-La chirurgie ................................ ................................ ............ 88",
    "a-Bilan préthérapeutique ................................ ................ 88",
    "c-Principe ................................ ................................ ........ 91",
    "2-L’imatinib (glivec®) ................................ .............................. 92",
    "3-La radio -chimiothérapie ................................ ......................... 93",
    "B-INDICATIONS THERAPEUTIQUES ................................ ........... 93",
    "1-Les tumeurs localisé es non métastatiques .............................. 93",
    "2-Tumeurs métastatiques ................................ ........................... 96",
    "3-Les récidives ................................ ................................ ........... 100",
    "4-Les reprogressions ................................ ................................ ..101",
    "5-Chimiothérapie et radiothérapie ................................ ............. 104",
    "a-Traitement adjuvant ................................ ..................... 104",
    "b-Traitement des formes avancées ou métastatiques ......105",
    "c-Radiothérapie ................................ ............................... 107",
    "C-PRONOSTIC ................................ ................................ ................... 108",
    "1-Résultat de la chirurgie ................................ ........................... 108",
    "2-Résultats du traitement par imatinib ................................ ......108",
    "a-L’étude de phase I ................................ ........................ 109",
    "b-L’étude de phase II ................................ ....................... 109",
    "c-L’étude de phase III ................................ ..................... 110",
    "3-Tolérance de l’imatinib ................................ .......................... 112",
    "4-Evaluation de la réponse tumorale sous imatinib ................... 113",
    "D-GIST ET IMATINIB ................................ ................................ ....... 116",
    "E-PERSPECTIVES D’AVENIR ................................ ......................... 121",
    "D’EXPERT) ................................ ................................ ..................... 122",
    "G-LA SURVEILLANCE ................................ ................................ .....125",
    "CONCLUSION ................................ ................................ ............... 126"
  ],
  "toc_start_page": 3,
  "toc_end_page": 10,
  "references_count": 27
}